These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 28680952)

  • 1. A Review of Fulvestrant in Breast Cancer.
    Nathan MR; Schmid P
    Oncol Ther; 2017; 5(1):17-29. PubMed ID: 28680952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence.
    Rocca A; Maltoni R; Bravaccini S; Donati C; Andreis D
    Cancer Manag Res; 2018; 10():3083-3099. PubMed ID: 30214302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.
    Reinert T; Barrios CH
    Ther Adv Med Oncol; 2017 Nov; 9(11):693-709. PubMed ID: 29344106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
    Bundred N
    Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
    Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
    Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
    Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
    Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
    Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer.
    Hamilton EP; Ma C; Laurentiis M; Iwata H; Hurvitz SA; Wander SA; Danso M; Lu DR; Smith JP; Liu Y; Tran L; Anderson S; Campone M
    Future Oncol; 2024 Jul; ():1-10. PubMed ID: 39072356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
    Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K; Curran MP; Plosker GL
    Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
    BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Krop IE; Mayer IA; Ganju V; Dickler M; Johnston S; Morales S; Yardley DA; Melichar B; Forero-Torres A; Lee SC; de Boer R; Petrakova K; Vallentin S; Perez EA; Piccart M; Ellis M; Winer E; Gendreau S; Derynck M; Lackner M; Levy G; Qiu J; He J; Schmid P
    Lancet Oncol; 2016 Jun; 17(6):811-821. PubMed ID: 27155741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fulvestrant for hormone-sensitive metastatic breast cancer.
    Lee CI; Goodwin A; Wilcken N
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011093. PubMed ID: 28043088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis.
    Xu L; Yan N; Li Z; Luo L; Wu X; Liu Q; Xu Y; Cao Y
    Onco Targets Ther; 2018; 11():8389-8398. PubMed ID: 30568462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives.
    Iorfida M; Mazza M; Munzone E
    Breast Cancer (Dove Med Press); 2020; 12():45-56. PubMed ID: 32256106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant.
    Kümler I; Knoop AS; Jessing CA; Ejlertsen B; Nielsen DL
    ESMO Open; 2016; 1(4):e000062. PubMed ID: 27843622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.